ReviewFrontiers in immunology2025
Multiple signaling pathways in the frontiers of lung cancer progression.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Smoker's Lungs: Quo Vadis? Exploring the Shared and Individual Smoking-Related Molecular Pathways of Emphysema, Carcinoma, and Fibrosis - An Illustrative Review.Thoracic cancer · 2026Review
- The potential utility of in-silico approach in identifying phytochemicals against various targets for the management of lung cancer.Discover oncology · 2026Review
- The Role of Hedgehog Signaling in Non-small Cell Lung Cancer: Targeting Tumor Invasion, Therapy Resistance and Novel Therapeutic Strategies.International journal of biological sciences · 2026Review
- Regulation of Human Lung Adenocarcinoma Cell Proliferation by LncRNA AFAP-AS1 Through the miR-508/ZWINT Axis.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is a prevalent malignant tumor and the leading cause of cancer-related mortality worldwide. LC is a complex respiratory condition that poses significant challenges for both clinicians and researchers. Crucially, dysregulation of molecular signaling pathways is a key message point in LC. Numerous reviews have highlighted effective treatments for LC by targeting disrupted signaling pathways. Understanding the roles and interconnections of various signaling pathways in LC is crucial. Therefore, this paper reviews the pathogenesis, biological functions and their important interactions in lung cancer. Frist, we reviewed relevant signaling pathways involved in LC, including Wnt, PI3K/Akt, Notch, PD-1/PD-L1, NF-κB, Hippo, MAPK, Hedgehog, AMPK. Immediately thereafter, we further explored the biological functions of LC in this area of pathophysiology, such as apoptosis, metastasis and proliferation. In conclusion, after our deeper understanding of the interactions of these signaling pathways in LC. And we must recognize that the interactions between the above signaling pathways can lead to comprehensive as well as novel therapeutic approaches for LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.